This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Events4SC（VSC）株式概要バイオ医薬品会社である4SC AGは、ドイツでアンメット・メディカル・ニーズの高いがん疾患に対応する低分子医薬品の開発に取り組んでいる。 詳細VSC ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( €202K )意味のある時価総額がありません ( €1M )すべてのリスクチェックを見るVSC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.106.6k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-23m16m2016201920222025202620282031Revenue €5.4kEarnings €979.5AdvancedSet Fair ValueView all narratives4SC AG 競合他社Genetic AnalysisSymbol: DB:8V8Market cap: €42.7mDextech MedicalSymbol: DB:LQ0Market cap: €185.8mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €127.3mbioXXmedSymbol: DB:T5OMarket cap: €222.9k価格と性能株価の高値、安値、推移の概要4SC過去の株価現在の株価€0.1052週高値€6.3052週安値€0.085ベータ2.341ヶ月の変化-80.39%3ヶ月変化-90.20%1年変化-97.42%3年間の変化-92.65%5年間の変化-98.74%IPOからの変化-99.91%最新ニュース分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...最新情報をもっと見るRecent updates分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024お知らせ • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023分析記事 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).お知らせ • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.お知らせ • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023お知らせ • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.株主還元VSCDE BiotechsDE 市場7D-56.5%1.9%2.0%1Y-97.4%-11.3%-0.1%株主還元を見る業界別リターン: VSC過去 1 年間で-11.3 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: VSCは、過去 1 年間で-0.1 % のリターンを上げたGerman市場を下回りました。価格変動Is VSC's price volatile compared to industry and market?VSC volatilityVSC Average Weekly Movement42.8%Biotechs Industry Average Movement8.9%Market Average Movement6.2%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: VSCの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: VSCの weekly volatility ( 43% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199714Jason Loveridgewww.4sc.comバイオ医薬品会社である4SC AGは、ドイツでアンメット・メディカル・ニーズの高い癌疾患に対応する低分子医薬品の開発に従事している。同社の製品であるResminostatは、経口投与のヒストン脱アセチル化酵素阻害剤で、皮膚T細胞リンパ腫の治療薬として臨床開発段階にある。また、製薬会社やバイオテクノロジー企業への製品導出も行っている。同社は1997年に設立され、ドイツのプラネッグに本社を置いている。もっと見る4SC AG 基礎のまとめ4SC の収益と売上を時価総額と比較するとどうか。VSC 基礎統計学時価総額€1.09m収益（TTM）-€7.68m売上高(TTM)€202.00k5.4xP/Sレシオ-0.1xPER（株価収益率VSC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計VSC 損益計算書（TTM）収益€202.00k売上原価€43.00k売上総利益€159.00kその他の費用€7.84m収益-€7.68m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.70グロス・マージン78.71%純利益率-3,800.50%有利子負債／自己資本比率0.0%VSC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/18 16:13終値2025/12/16 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋4SC AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Linda PomeroyEdison Investment ResearchMarcus WieprechtStifel, Equities Research
分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).
お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024
お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024
お知らせ • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.
Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023
分析記事 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...
Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).
お知らせ • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.
お知らせ • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023
お知らせ • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023
Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.
Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.
